Results 61 to 70 of about 9,117 (217)
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source
The influence of hepatitis C infection and interferon-α therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report [PDF]
, 2009 Background Hepatitis C virus is a highly immunogenic pathogen often inducing autoimmune activation changes and this can often be further exacerbated by Interferon therapy.
Huy A Tran, Glenn EM Reeves
core +1 more source
Graves Ophthalmopathy: A Review of Immunogenetics [PDF]
Current Genomics, 2011 Graves' disease (GD) is the most common cause of thyrotoxicosis and often involves the orbits. Graves' ophthalmopathy (GO), also known as Thyroid Eye Disease (TED), can be clinically significant and advance to sight-threatening stages. Our knowledge of the immunogenetic pathophysiology of GO is rapidly expanding.
Khalilzadeh, Omid +3 more
openaire +2 more sources
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu +3 more
wiley +1 more source
Treatment of Graves' ophthalmopathy
Клиническая и экспериментальная тиреоидология, 2010 Graves' ophthalmopathy is one of most frequent extrathyroid manifestation of autoimmune thyroid diseases. In 3–5% cases it has severe progress and requires specific therapy.
doaj +1 more source
Selenium improves mild Graves’Orbitopathy: a randomized, double-blind, placebo-controlled study. [PDF]
, 2011 Background Free oxygen radicals and cytokines play a pathogenic role in Graves’ orbitopathy (GO). This study reports the results of a randomized, double-blind, placebo-controlled trial on the effect of selenium, an antioxidant agent, or pentoxifylline ...
ALTEA, MARIA ANTONIETTA
core
The thyroid, the eyes and the gut: a possible connection [PDF]
, 2017 Graves’ disease (GD) is an autoimmune disorder responsible for 60–90% of thyrotoxicosis, with an incidence of 1 to 2 cases per 1000 population per year in England.
Covelli, D., Ludgate, Marian Elizabeth
core +2 more sources
Journal of Ophthalmology, Volume 2026, Issue 1, 2026.Purpose The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG
Wanicha Chuenkongkaew +7 more
wiley +1 more source
Journal of Patient-Reported Outcomes, 2019 Purpose To develop and assess the psychometric properties of the Thai version of the Graves’ Ophthalmopathy Quality of Life (GO-QOL) questionnaire. Background Graves’ ophthalmopathy (GO) is a chronic condition that causes negative self-image and impaired
Mingkwan Lumyongsatien +8 more
doaj +1 more source
Evaluation of the patients with Grave’s ophthalmopathy after the corticosteroids treatment [PDF]
Vojnosanitetski Pregled, 2012 Background/Aim. Graves’ ophthalmopthy is one of the most common causes of exophthalmos as well as the most common manifestation of Graves’ disease. The treatment of Graves’ ophthalmopathy includes ophthalmological and endocrinological therapy. The aim
Janićijević-Petrović Mirjana +5 more
doaj +1 more source